Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-Study)

被引:60
作者
Holz, FG
Jorzik, J
Schutt, F
Flach, U
Unnebrink, K
机构
[1] Univ Heidelberg, Dept Ophthalmol, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, Coordinat Ctr Clin Trials, Heidelberg, Germany
关键词
D O I
10.1016/S0161-6420(02)01770-0
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To determine intraobserver and interobserver variation for classifying types of choroidal neovascularizations (CNV) in exudative age-related macular degeneration (ARMD). Design: Intraexaminer and interexaminer reliability study. Participants: Digital high-quality fluorescein angiograms of 40 patients with neovascular ARMD were evaluated independently by 16 retinal specialists. Main Outcome Measures: Fluorescein angiographies were presented in two randomized sequences (series A and B) to each masked reader for classification of type of CNV into classic, occult, or mixed with classic component of less or greater 50%. Agreement was evaluated by calculating kappa statistics (kappa) and intraclass correlation coefficients. Results: The mean kappa coefficient was 0.64 +/- 0.11 for intraobserver variation, with a range from 0.44 to 0.89. For interobserver variation the intraclass correlation coefficients was calculated as 0.66 (95% confidence interval [Cl] 0.56, 0.77) for series A and as 0.55 (95% Cl 0.43, 0.67) for series B. Conclusions: Angiographic classification of CNV secondary to ARMD can vary considerably not only between observers but also for repeated evaluation by the same observer. Because various current and emerging treatments including photodynamic therapy are based on specific angiographic characteristics, accurate interpretation will become more important. Ophthalmology 2003;110:400-405 (C) 2003 by the American Academy of Ophthalmology.
引用
收藏
页码:400 / 405
页数:6
相关论文
共 34 条
[1]  
ABRAMS LS, 1994, OPHTHALMOLOGY, V101, P1662
[2]  
Altman D.G., 1991, PRACTICAL STAT MED R, V1st, P403, DOI [10.1002/sim.4780101015, DOI 10.1002/SIM.4780101015]
[3]  
Arnold J, 2001, AM J OPHTHALMOL, V131, P541
[4]  
Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
[5]  
Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
[6]   Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up [J].
Challa, JK ;
Gillies, MC ;
Penfold, PL ;
Gyory, JF ;
Hunyor, ABL ;
Billson, FA .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, 1998, 26 (04) :277-281
[7]   Age-related macular degeneration: A review of experimental treatments [J].
Ciulla, TA ;
Danis, RP ;
Harris, A .
SURVEY OF OPHTHALMOLOGY, 1998, 43 (02) :134-146
[8]   THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].
DAMATO, RJ ;
LOUGHNAN, MS ;
FLYNN, E ;
FOLKMAN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085
[9]   Translocation of the retina for management of subfoveal choroidal neovascularization - II: A preliminary report in humans [J].
de Juan, E ;
Loewenstein, A ;
Bressler, NM ;
Alexander, J .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 125 (05) :635-646
[10]   Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration [J].
Eckardt, C ;
Eckardt, U ;
Conrad, HG .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1999, 237 (04) :313-325